With an upgrade and an initiation at "Buy" on Wednesday morning, Achillion (ACHN) is back in the good graces of at least some biotech investors. I've been favorably inclined
towards Achillion for a while now, thinking that its NS3 protease
inhibitor sovaprevir (aka ACH-1625) and NS5a inhibitor (ACH-3102) gave
it a better-than-average chance of being a player in the hepatitis C
(HCV) market or, more likely, a target for a company that fears being
left on the outside of this eventual multi-billion dollar market.
Please read more here:
Achillion Back On The Hep C Roller Coaster Of Love
No comments:
Post a Comment